Skip to main content
. 2021 Aug 11;13(16):4040. doi: 10.3390/cancers13164040

Figure 2.

Figure 2

PI3K/Akt inactivation combined with immunomodulatory agents. Inhibition of PI3K or Akt decreases PD-L1 expression in cancer cells, contributing to the efficacy of anti-PD1 treatment. PI3K inhibitors in combination with different inhibitors (anti-CTLA4, BRAFi, BTKi, MEKi, Proteasome inhi) improves T cell killing activity against cancer cells (Created with BioRender.com: agreement number ZU22NUG38X).